TNP-470 ANTIANGIOGENIC THERAPY FOR ADVANCED MURINE NEUROBLASTOMA

The finding that angiogenesis prays an important role in the progressi on and metastasis of malignant tumors has led to the development of se veral antiangiogenic drugs. The authors report here an examination of the effect of the antiangiogenic agent TNP-470 on the growth, metastas es, and survival of two differing murine neuroblastoma cell lines, TBJ and C1300. We found that TNP-470 significantly reduced primary tumor volumes in mice injected with either cell line. In addition, antiangio genic therapy significantly reduced the size of axillary lymph node me tastases in both groups as well as decreased the size of liver metasta ses in mice receiving TBJ neuroblastoma. TNP-470 treatment also improv ed animal survival. These data suggest that antiangiogenic therapy ret ards the growth of primary and metastatic murine neuroblastoma. We spe culate that antiangiogenic therapy may be a useful therapeutic modalit y in the treatment of advanced neuroblastoma once side effects and app ropriate dosage requirements are determined. Copyright (C) 1997 by W.B . Saunders Company.